Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2025)

Historic Non-Current Deffered Revenue for BridgeBio Pharma (BBIO) over the last 3 years, with Q3 2025 value amounting to $13.1 million.

  • BridgeBio Pharma's Non-Current Deffered Revenue fell 2950.56% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 2950.56%. This contributed to the annual value of $17.1 million for FY2024, which is 35867.99% up from last year.
  • BridgeBio Pharma's Non-Current Deffered Revenue amounted to $13.1 million in Q3 2025, which was down 2950.56% from $14.7 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Non-Current Deffered Revenue high stood at $19.9 million for Q1 2024, and its period low was $3.7 million during Q4 2023.
  • For the 3-year period, BridgeBio Pharma's Non-Current Deffered Revenue averaged around $15.2 million, with its median value being $17.0 million (2024).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 35867.99% in 2024, then crashed by 2950.56% in 2025.
  • BridgeBio Pharma's Non-Current Deffered Revenue (Quarter) stood at $3.7 million in 2023, then skyrocketed by 358.68% to $17.1 million in 2024, then decreased by 23.19% to $13.1 million in 2025.
  • Its last three reported values are $13.1 million in Q3 2025, $14.7 million for Q2 2025, and $17.5 million during Q1 2025.